article thumbnail

SAVE THE DATE: Drug Channels Leadership Forum, March 17-19, 2025

Drug Channels

This unique, new event will be held from March 17 to 19, 2025, at the Turnberry Resort and Spa in Miami. I am pleased to announce the inaugural Drug Channels Leadership Forum !

article thumbnail

4 AI predictions for the Life Sciences Sector by 2025

H1 Blog

By 2025, we can anticipate pretty significant shifts as AI continues to advance and integrate into various processes within the healthcare ecosystem. We predict that by 2025 we will see more widespread use of AI in recruiting patients for clinical trials. Here are 4 predictions for how life sciences companies might be using AI by then.

Science 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

$225m to advance novel immune checkpoint enhancer programme

Drug Discovery World

ALTB-268 is currently being studied in a Phase IIa exploratory biomarker study in patients with biologic refractory UC with an anticipated readout for its primary endpoint of clinical remission per modified Mayo score in 1H 2025.

article thumbnail

Researchers Find New Way to Curb Asthma Attacks

Drugs.com

TUESDAY, March 26, 2025 -- A protein that shuts down immune cells in the lungs could be key to a new treatment for asthma attacks, a new report says.The naturally occurring protein, called Piezo1, prevents a type of immune cell called type 2 innate.

article thumbnail

Mandatory EU HTAR Implementation: Part 1

thought leadership

Are You Ready for Mandatory EU Health Technology Assessment Regulation (HTAR) Implementation Beginning January 2025? Pharmaceutical companies need to be prepared for the new European Health Technology Assessment Regulation (HTAR), which will take effect in January 2025.

article thumbnail

Financing extension for small molecule neoantigen immuno-oncology company 

Drug Discovery World

With the support of our committed and new investors, along with our research collaborations with academic institutions that are in place, we remain on track to deliver a candidate drug for our lead PMS2 programme by early 2025.” The post Financing extension for small molecule neoantigen immuno-oncology company appeared first on Drug Discovery World (..)

article thumbnail

GSK Consumer Healthcare commits to make over a billion toothpaste tubes recyclable by 2025 as part of its ongoing sustainability journey

The Pharma Data

It is anticipated that the combined moves will see over a billion toothpaste tubes per year become recyclable by 2025. We have made the commitment that 100% of our product packaging will be recyclable or reusable, where quality and safety permits, by 2025.This